The assay aims to identify compounds that modulate the activity of the KCNH2 3.1 potassium channel, a brain selective isoform that is increased in the brains of patients with schizophrenia. The assay uses a high throughput thallium flux assay developed for KCNH2 and will screen compounds for their ability to selectively modulate the KCNH2 3.1 isoform. The resulting compounds will be validated in electrophysiology experiments and animal models will be used to test for effects on memory and other aspects of animal physiology linked with psychosis. The aim is to develop antipsychotic drugs without cardiac side effects. Is the molecule effective to this assay?